title: Disease modification and cardiovascular risk reduction: two sides of the same coin?
abstract: Inflammatory rheumatic diseases are associated with a substantial increase in accelerated atherosclerosis, with complex interactions between traditional and disease-related risk factors. Therefore, cardiovascular risk reduction should be considered as integral to the control of disease activity in the care plans of patients with RA, SLE and, arguably any chronic inflammatory disease. Shared care structures, already established for the monitoring of DMARDs, could be adapted to communicate and monitor cardiovascular risk reduction objectives. We review the evidence for the efficacy of a range of therapeutic strategies, the majority of which impact on both disease activity and cardiovascular risk. The algorithm proposed here attempts to distil the latest advice from specialist panels at the National Cholesterol Education Program and the British Hypertension Society, as well as incorporating the existing data on SLE and RA patients. The algorithm is structured to minimize clinic time and resources necessary to stratify patients into groups for ROUTINE, SUBSTANTIAL or INTENSIVE risk management; the associated table summarizes optimal therapeutic objectives in each of these groups. The implication of this algorithm is that management of cardiovascular risk should be much more aggressive than is currently the norm in patients with chronic inflammatory diseases, such as RA and SLE. Long-term studies of such interventions are needed to further clarify the benefits of intensive cardiovascular risk management in these patients.
authors.affiliation: University of Cambridge School of Medicine, UK. fch22@medschl.cam.ac.uk
authors.forename: F C
authors.initials: FC
authors.lastname: Hall
authors.forename: N
authors.initials: N
authors.lastname: Dalbeth
mesh_terms: D000465:Algorithms; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications; D050197:Atherosclerosis / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D012216:Rheumatic Diseases / Q000150:complications* / Q000188:drug therapy
chemical_list: D018501:Antirheumatic Agents